Roberto Salgado
Impact in
- Cancer Research top 0.02%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- Oncology top 0.05%
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
Papers in
- Cancer Research 189
- Breast Cancer Treatment Studies 136
- Cancer Genomics and Diagnostics 59
- Oncology 108
- Cancer Immunotherapy and Biomarkers 74
- HER2/EGFR in Cancer Research 25
- Co-authors
- Sherene Loi (52 shared papers)Christos P. Sotiriou (32 shared papers)Peter Stephen Savas (19 shared papers)Stefan Michiels (17 shared papers)Carsten Denkert (13 shared papers)Martine J Piccart (17 shared papers)Mark John Smyth (3 shared papers)Nicolas Sirtaine (6 shared papers)
- Journals
- Annals of Oncology (32 papers)Nature Communications (25 papers)npj Breast Cancer (19 papers)Nature (15 papers)The Lancet Oncology (10 papers)
- Partner nations
- BelgiumAustraliaUnited States
In The Last Decade
Roberto Salgado
296 papers receiving 35.2k citations
Roberto Salgado's Hit Papers
Peers
Comparison fields: 5 of 166
- Cancer Research 14.1k
- Oncology 12.8k
- Immunology 2.4k
- Pathology and Forensic Medicine 1.5k
- Pulmonary and Respiratory Medicine 2.7k
Countries citing papers authored by Roberto Salgado
This map shows the geographic impact of Roberto Salgado's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roberto Salgado with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roberto Salgado more than expected).
Fields of papers citing papers by Roberto Salgado
This network shows the impact of papers produced by Roberto Salgado. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roberto Salgado. The network helps show where Roberto Salgado may publish in the future.
Co-authors
The 25 scholars most cited alongside Roberto Salgado, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 313 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014 Hit paper breakdown → | 2014 | 2494 |
| 2 | The repertoire of mutational signatures in human cancer Hit paper breakdown → | 2020 | 2401 |
| 3 | Pan-cancer analysis of whole genomes Hit paper breakdown → | 2020 | 2169 |
| 4 | Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98 Hit paper breakdown → | 2013 | 1379 |
| 5 | Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial Hit paper breakdown → | 2014 | 1073 |
| 6 | CD4+ follicular helper T cell infiltration predicts breast cancer survival Hit paper breakdown → | 2013 | 890 |
| 7 | Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis Hit paper breakdown → | 2018 | 814 |
| 8 | Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis Hit paper breakdown → | 2017 | 770 |
| 9 | Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial Hit paper breakdown → | 2019 | 759 |
| 10 | The evolutionary history of 2,658 cancers Hit paper breakdown → | 2020 | 730 |
| 11 | Clinical relevance of host immunity in breast cancer: from TILs to the clinic Hit paper breakdown → | 2015 | 723 |
| 12 | Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers Hit paper breakdown → | 2019 | 665 |
| 13 | The 2019 World Health Organization classification of tumours of the breast Hit paper breakdown → | 2020 | 648 |
| 14 | Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors Hit paper breakdown → | 2017 | 635 |
| 15 | Patterns of somatic structural variation in human cancer genomes Hit paper breakdown → | 2020 | 564 |
| 16 | Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research Hit paper breakdown → | 2017 | 560 |
| 17 | Lung adenocarcinoma promotion by air pollutants Hit paper breakdown → | 2023 | 546 |
| 18 | 2015 | 507 | |
| 19 | Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group Hit paper breakdown → | 2020 | 507 |
| 20 | Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing Hit paper breakdown → | 2020 | 489 |
About Roberto Salgado
Roberto Salgado is a scholar working on Cancer Research, Oncology, Artificial Intelligence, Genetics and Pulmonary and Respiratory Medicine, having authored 313 papers that have together received 35.8k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (136 papers), Cancer Immunotherapy and Biomarkers (74 papers), Cancer Genomics and Diagnostics (59 papers), AI in cancer detection (35 papers), HER2/EGFR in Cancer Research (25 papers), Breast Lesions and Carcinomas (9 papers), Genomic variations and chromosomal abnormalities (7 papers) and Clinical Laboratory Practices and Quality Control (6 papers). The work is most often cited by research in Cancer Research (14.1k citations), Oncology (12.8k citations), Immunology (2.4k citations), Pathology and Forensic Medicine (1.5k citations) and Pulmonary and Respiratory Medicine (2.7k citations). Roberto Salgado has collaborated with scholars based in Belgium, Australia and United States. Frequent co-authors include Sherene Loi, Christos P. Sotiriou, Peter Stephen Savas, Stefan Michiels, Carsten Denkert, Martine J Piccart, Mark John Smyth, Nicolas Sirtaine, Evandro de Azambuja and Stephen James Luen. Their work appears in journals such as Annals of Oncology, Nature Communications, npj Breast Cancer, Nature and The Lancet Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.